Search Results - "Stoter, G."

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11) by MATHIJSSEN, Ron H. J, VAN ALPHEN, Robbert J, VERWEIJ, Jaap, LOOS, Walter J, NOOTER, Kees, STOTER, Gerrit, SPARREBOOM, Alex

“…CPT-11 belongs to the class of topoisomerase I inhibitors, and it acts as a prodrug of SN-38, which is approximately 100–1000-fold more cytotoxic than the…”
Get full text

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients by DE JONGH, F. E, VAN VEEN, R. N, VELTMAN, S. J, DE WIT, R, VAN DER BURG, M. E. L, VAN DEN BENT, M. J, PLANTING, Asth, GRAVELAND, W. J, STOTER, G, VERWEIJ, J

“…In the present study we describe the toxicity of weekly high-dose (70-85 mg x m(-2)) cisplatin in 400 patients (203 men, 197 women; median age 54 years) with…”
Get full text

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists by DE BOER-DENNERT, M, DE WIT, R, SCHMITZ, P. I. M, DJONTONO, J, BEURDEN, V. V, STOTER, G, VERWEIJ, J

“…In 1983, Coates conducted a survey that ranked the side-effects perceived by patients receiving chemotherapy in the order of their severity. Vomiting and…”
Get full text

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy by DE WIT, R, DE BOER, A. C, VD LINDEN, G. H. M, STOTER, G, SPARREBOOM, A, VERWEIJ, J

“…In view of the similarity in chemical structure of the available 5HT(3)-receptor antagonists it is assumed, whilst these agents all act at the same receptor,…”
Get full text

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report by Marchand, M, Punt, C.J.A, Aamdal, S, Escudier, B, Kruit, W.H.J, Keilholz, U, Håkansson, L, van Baren, N, Humblet, Y, Mulders, P, Avril, M.-F, Eggermont, A.M.M, Scheibenbogen, C, Uiters, J, Wanders, J, Delire, M, Boon, T, Stoter, G

“…Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant…”
Get full text

Thalidomide in solid tumours: the resurrection of an old drug by Sleijfer, Stefan, Kruit, Wim H.J., Stoter, Gerrit

“…Following reports of its teratogenicity, thalidomide was banned from the market in the 1960s. Later, the elucidation that the inhibition of angiogenesis…”
Get full text

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group by de Wit, R, Stoter, G, Kaye, S B, Sleijfer, D T, Jones, W G, ten Bokkel Huinink, W W, Rea, L A, Collette, L, Sylvester, R

“…This prospective randomized trial was designed to compare the efficacy of etoposide plus cisplatin (EP) versus bleomycin, etoposide, and cisplatin (BEP)…”
Get more information

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer by VAN DER BURG, M. E. L, DE WIT, R, VAN PUTTEN, W. L. J, LOGMANS, A, KRUIT, W. H. J, STOTER, G, VERWEIJ, J

“…We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in patients with platinum-refractory…”
Get full text

Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer by Travis, Lois B., Curtis, Rochelle E., Fraumeni, Joseph F., Boice, John D., Storm, Hans, Andersson, Michael, Hall, Per, Bergfeldt, Kjell, Holowaty, Eric, Clarke, E. Aileen, Van Leeuwen, Flora E., Kohler, Betsy A., Pukkala, Eero, Pukkala, Eero, Wiklund, Tom, Stoter, Gerritt, Gospodarowicz, Mary, Sturgeon, Jeremy

“…Background: We have quantified the site-specific risk of second malignant neoplasms among nearly 29 000 survivors (⩾1 year) of testicular cancer, taking into…”
Get full text

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens by Burger, H., den Bakker, M.A., Stoter, G., Verweij, J., Nooter, K.

“…Previous studies have shown that STI571, a selective tyrosine kinase inhibitor of c-KIT, is highly effective in c-KIT/CD117-positive gastrointestinal stromal…”
Get full text

Molecular Mechanisms of Multidrug Resistance in Cancer Chemotherapy by Nooter, K., Stoter, G.

“…The occurrence of multidrug resistance (MDR) is one of the main obstacles in the successful chemotherapeutic treatment of cancer. MDR cell lines are resistant…”
Get full text

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy by POLES, M. B, HOP, W. C. J, KOK, T. C, ESKENS, Falm, VAN DER BURG, M. E. L, SPLINTER, T. A. W, SIERSEMA, P. D, TILANUS, H. W, STOTER, G, VAN DER GAAST, A

“…The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are treated with cisplatin-based…”
Get full text

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients by DE WIT, R, KRUIT, W. H. J, STOTER, G, DE BOER, M, KERGER, J, VERWEIJ, J

“…The semisynthetic taxoid docetaxel was investigated in a phase II study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty…”
Get full text

Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure by DE JONGH, Felix E, VERWEIJ, Jaap, LOOS, Walter J, DE WIT, Ronald, DE JONGE, Maja J. A, PLANTING, André S. T, NOOTER, Kees, STOTER, Gerrit, SPARREBOOM, Alex

“…Most anticancer drugs are dosed based on body-surface area (BSA) to reduce interindividual variability of drug effects. We evaluated the relevance of this…”
Get full text

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development by GERRITS, C. J. H, DE JONGE, M. J. A, SCHELLENS, J. H. M, STOTER, G, VERWEIJ, J

“…Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for clinical use in ovarian cancer…”
Get full text

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer by POLEE, M. B, ESKENS, Falm, VAN DER BURG, M. E. L, SPLINTER, T. A. W, SIERSEMA, P. D, TILANUS, H. W, VERWEIJ, J, STOTER, G, VAN DER GAAST, A

“…In a phase I study we demonstrated the feasibility of a bi-weekly combination of paclitaxel 180 mg x m(-2) with cisplatin 60 mg x m(-2). In this study we…”
Get full text

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group by DE WIT, R, STOTER, G, SLEIJFER, D. T, NEIJT, J. P, TEN BOKKEL HUININK, W. W, DE PRIJCK, L, COLLETTE, L, SYLVESTER, R

Get full text

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial by ten Tije, A.J, Smorenburg, C.H, Seynaeve, C, Sparreboom, A, Schothorst, K.L.C, Kerkhofs, L.G.M, van Reisen, L.G.P.M, Stoter, G, Bontenbal, M, Verweij, J

“…Paclitaxel is a cytotoxic agent with proven antitumour activity in metastatic breast cancer. Weekly administration of paclitaxel has demonstrated sustained…”
Get full text

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles by VAN ZUYLEN, Lia, KARLSSON, Mats O, VERWEIJ, Jaap, BROUWER, Eric, DE BRUIJN, Peter, NOOTER, Kees, STOTER, Gerrit, SPARREBOOM, Alex

“…Nonlinear disposition of paclitaxel (Taxol) in cancer patients has been described in several studies, but the underlying mechanism is still a matter of…”
Get full text

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 by SCHUYER, M, VAN DER BURG, M. E. L, HENZEN-LOGMANS, S. C, FLERET, J. H, KLIJN, J. G. M, LOOK, M. P, FOEKENS, J. A, STOTER, G, BERNS, Emjj

“…Traditional clinicopathological features do not predict which patients will develop chemotherapy resistance. The TP53 gene is frequently altered in ovarian…”
Get full text